TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Capricor Therapeutics ( (CAPR) ) has provided an announcement.
On December 3, 2025, Capricor Therapeutics announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial evaluating Deramiocel in boys and young men with Duchenne muscular dystrophy. The trial demonstrated statistically significant improvements in both skeletal and cardiac function, meeting its primary and key secondary endpoints. These results highlight Deramiocel’s potential as a first-in-class therapy for Duchenne cardiomyopathy, a leading cause of mortality in DMD. The company, in collaboration with its commercial partner Nippon Shinyaku, is advancing launch readiness activities to support patient access, pending regulatory approval.
The most recent analyst rating on (CAPR) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Capricor Therapeutics stock, see the CAPR Stock Forecast page.
Spark’s Take on CAPR Stock
According to Spark, TipRanks’ AI Analyst, CAPR is a Neutral.
Capricor Therapeutics’ overall stock score is primarily impacted by its financial struggles, including persistent losses and cash flow issues. While technical analysis and earnings call insights provide some positive outlooks, the valuation challenges and regulatory hurdles weigh heavily on the stock’s attractiveness.
To see Spark’s full report on CAPR stock, click here.
More about Capricor Therapeutics
Capricor Therapeutics is a biotechnology company focused on developing transformative cell and exosome-based therapeutics for rare diseases. Its lead product candidate, Deramiocel, is an allogeneic cardiac-derived cell therapy in late-stage clinical development for Duchenne muscular dystrophy (DMD).
Average Trading Volume: 1,595,651
Technical Sentiment Signal: Sell
Current Market Cap: $304M
For detailed information about CAPR stock, go to TipRanks’ Stock Analysis page.